Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TNN002
MIFTS: 38

Tinea Unguium

Categories: Infectious diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tinea Unguium

About this section

MalaCards integrated aliases for Tinea Unguium:

Name: Tinea Unguium 12 15 74
Cellulitis and Abscess of Upper Arm and Forearm 12
Cellulitis and Abscess of Finger and Toe 12
Cellulitis and Abscess of Gluteal Region 12
Cellulitis and Abscess of Buttock 12
Onychomycosis Due to Dermatophyte 12
Cellulitis and Abscess of Finger 12
Cellulitis and Abscess of Trunk 12
Cellulitis and Abscess of Face 12
Dermatophytic Onychomycosis 12
Dermatophytosis of Nail 12
Cellulitis and Abscess 12
Dermatophytic Onychia 12
Onychomycosis 74

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:13074
ICD9CM 36 681.9
ICD10 34 B35.1
Sources

Summaries for Tinea Unguium

About this section
Disease Ontology : 12 A dermatophytosis that results in fungal infection located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which cause separation of the nail plate from the nail bed and has symptom thickening of subungueal area. Sometimes, white islands are seen on the external nail plates. These gradually coalesce until the entire nail plate is involved.

MalaCards based summary : Tinea Unguium, also known as cellulitis and abscess of upper arm and forearm, is related to tinea pedis and tinea corporis, and has symptoms including thickening of subungueal area An important gene associated with Tinea Unguium is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways is Type II interferon signaling (IFNG). The drugs Miconazole and Amorolfine have been mentioned in the context of this disorder. Affiliated tissues include testes and nail.

Wikipedia : 77 Onychomycosis, also known as tinea unguium, is a fungal infection of the nail. Symptoms may include... more...

Sources

Related Diseases for Tinea Unguium

About this section

Diseases related to Tinea Unguium via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 26)
# Related Disease Score Top Affiliating Genes
1 tinea pedis 31.3 ARSI SQLE
2 tinea corporis 30.5 ARSI SQLE
3 dermatophytosis 10.4
4 cellulitis 10.4
5 uvulitis 10.4
6 erythema multiforme 10.2
7 neuritis 10.2
8 tinea capitis 10.2
9 human immunodeficiency virus infectious disease 10.2
10 orbital cellulitis 10.2
11 dermatomycosis 10.1
12 tinea cruris 10.1 PPIG SQLE
13 dacryocystitis 10.0
14 separation anxiety disorder 10.0 HLA-B OPRM1
15 dengue hemorrhagic fever 9.9 HLA-B STAT1
16 crohn's disease 9.8
17 crohn's colitis 9.8
18 acute dacryocystitis 9.8
19 central retinal artery occlusion 9.8
20 hidradenitis suppurativa 9.8
21 hidradenitis 9.8
22 retinal artery occlusion 9.8
23 impetigo 9.8
24 fasciitis 9.8
25 necrotizing fasciitis 9.8
26 scleredema 9.8

Graphical network of the top 20 diseases related to Tinea Unguium:



Diseases related to Tinea Unguium
Sources

Symptoms & Phenotypes for Tinea Unguium

About this section

Symptoms:

12
  • • thickening of subungueal area
Sources

Drugs & Therapeutics for Tinea Unguium

About this section

Drugs for Tinea Unguium (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
3
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
4
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 5402 1549008
5
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
6
carbamide peroxide Approved Phase 4,Phase 3,Not Applicable 124-43-6
7
Bifonazole Approved, Investigational Phase 4,Phase 3,Not Applicable 60628-96-8 2378
8
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 84625-61-6 55283
9
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
10
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
11
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Keratolytic Agents Phase 4,Not Applicable
19 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
21 Dermatologic Agents Phase 4,Not Applicable
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24
Hydroxyitraconazole Phase 4,Phase 3,Phase 2,Early Phase 1
25 Antiprotozoal Agents Phase 4,Phase 2,Not Applicable
26 Antiparasitic Agents Phase 4,Phase 2,Not Applicable
27 Anti-Bacterial Agents Phase 4,Not Applicable
28 Protective Agents Phase 4
29 Free Radical Scavengers Phase 4
30 Liposomal amphotericin B Phase 4
31 Antioxidants Phase 4
32
Luliconazole Approved Phase 2, Phase 3,Phase 1 187164-19-8
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34 Cytochrome P-450 CYP2C19 Inhibitors Phase 3
35
Econazole Approved Phase 2 27220-47-9 3198
36
Naftifine Approved Phase 2 65472-88-0 47641 73342
37
Posaconazole Approved, Investigational, Vet_approved Phase 2,Not Applicable 171228-49-2 147912
38
Aminolevulinic acid Approved Phase 2,Not Applicable 106-60-5 137
39 Albaconazole Investigational Phase 2,Phase 1 187949-02-6
40
Ketoconazole Approved, Investigational Phase 1 65277-42-1 47576
41 Tin Fluorides Phase 1
42
Methylene blue Approved, Investigational Not Applicable 61-73-4
43
Tea tree oil Approved Not Applicable
44
Voriconazole Approved, Investigational Not Applicable 137234-62-9 71616
45
Petrolatum Approved, Investigational Early Phase 1 8009-03-8
46 Photosensitizing Agents Not Applicable
47 English Lavender Not Applicable
48 Tea Not Applicable
49 Tea Tree Not Applicable

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
4 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
5 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
6 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
7 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
8 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
9 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
10 Study Evaluating the Effect of Jublia on Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
11 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
12 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
13 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
14 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
15 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
16 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
17 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
18 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
19 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
20 Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
21 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
22 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
23 Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
24 Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population Completed NCT02547701 Phase 3 P-3058
25 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
26 Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
27 PinPointe FootLaser for the Treatment of Onychomycosis Completed NCT00935649 Phase 2, Phase 3
28 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
29 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
30 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
31 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
32 Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
33 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Active, not recruiting NCT03168841 Phase 3 Efinaconazole Topical
34 Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
35 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Active, not recruiting NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
36 Antifungal Drugs in Treatment of Onychomycosis Not yet recruiting NCT03171584 Phase 3 Terbinafine
37 Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
38 Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails Terminated NCT01208129 Phase 3 NAB001;Placebo control
39 Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
40 Using Light Therapy to Treat Toe Nail Fungus Unknown status NCT00771732 Phase 2
41 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
42 Erbium-doped Yttrium Aluminium Garnet Laser(Er:Yag)Associated With Amorolfine Lacquer in the Treatment of Onychomycosis Unknown status NCT01528813 Phase 2 Amorolfine lacquer
43 A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail Unknown status NCT00385502 Phase 2 EcoNailâ„¢ (econazole 5%/SEPA® 18% nail lacquer)
44 Topical Gel Anti-Fungal Agent for Tinea Unguium Completed NCT00253305 Phase 2 Organogel of naftifine, 2%;Organogel of terbinafine, 2%;Organogel of naftifine, 6%;Organogel of terbinafine, 6%
45 Safety & Efficacy Study of HTU-520 in the Treatment of Distal Subungual Onychomycosis of the Toenail Completed NCT01400594 Phase 2 HTU-520 Patch
46 A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED) Completed NCT00491764 Phase 2 SCH 56592;SCH 56592;SCH 56592;SCH 56592;Terbinafine;Placebo
47 Study of Different Doses of a Novel Treatment for Onychomycosis Completed NCT00679965 Phase 2 AN2690, 2.5%;AN2690, 5%;AN2690, 7.5%;AN2690 Solution Vehicle
48 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail Completed NCT02267356 Phase 2 VT-1161;Placebo
49 Study of Different Doses of a Novel Treatment for Onychomycosis Completed NCT00679770 Phase 2 AN2690, 2.5%;AN2690, 5%;AN2690, 7.5%;Vehicle
50 Efficacy and Safety Study of Iontophoretic Application of Terbinafine Gel in Subjects With Onychomycosis Completed NCT01080079 Phase 2 Terbinafine Hydrochloride

Search NIH Clinical Center for Tinea Unguium

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Tinea Unguium

About this section
Sources

Anatomical Context for Tinea Unguium

About this section

MalaCards organs/tissues related to Tinea Unguium:

42
Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Tinea Unguium:

20
Nail
Sources

Publications for Tinea Unguium

About this section

Articles related to Tinea Unguium:

(show top 50) (show all 55)
# Title Authors Year
1
Response to: Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ( 29951161 )
2018
2
Tinea unguium onychomycosis caused by dermatophytes: a ten-year retrospective study (2005-2014) in a tertiary hospital in Singapore. ( 29552686 )
2018
3
Comment on "Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia". ( 29849837 )
2018
4
Topical efinaconazole: A promising therapeutic medication for tinea unguium. ( 30035311 )
2018
5
Ultrastructural changes of Trichophyton rubrum in tinea unguium after itraconazole therapy in vivo observed using scanning electron microscopy. ( 30387190 )
2018
6
Prevalence, Etiology, and Risk Factors of Tinea Pedis and Tinea Unguium in Tunisia. ( 28852411 )
2017
7
Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. ( 28281037 )
2017
8
Examining the accuracy of visual diagnosis of tinea pedis and tinea unguium in aged care facilities. ( 28379097 )
2017
9
Tinea Unguium: Diagnosis and Treatment in Practice. ( 27787643 )
2016
10
Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes. ( 26992478 )
2016
11
Is the Dermatophyte Test Strip truly useful for the diagnosis of tinea unguium? Inquiry into "Clinical study of Dermatophyte Test Strip, an immunochromatographic method, to detect tinea unguium dermatophytes". ( 27910169 )
2016
12
Diagnostic accuracy of tinea unguium based on clinical observation. ( 25545551 )
2015
13
Screening for tinea unguium by thermography in older adults with subungual hyperkeratosis. ( 25311983 )
2014
14
Candida galli as a cause of tinea unguium-molecular characterization of a rare clinical fungal entity. ( 25037486 )
2014
15
A retrospective cohort study of tinea pedis and tinea unguium in inpatients in a psychiatric hospital. ( 24943206 )
2014
16
Screening for Tinea Unguium by Dermatophyte Test Strip. ( 24117339 )
2013
17
Rapid real-time diagnostic PCR for Trichophyton rubrum and Trichophyton mentagrophytes in patients with tinea unguium and tinea pedis using specific fluorescent probes. ( 23287391 )
2013
18
Disseminated erythema multiforme-like reaction triggered by tinea unguium. ( 21554422 )
2011
19
Optimized 5-hour multiplex PCR test for the detection of tinea unguium: performance in a routine PCR laboratory. ( 20105101 )
2010
20
Commentary: the illusory tinea unguium cure. ( 20159309 )
2010
21
Preventing long term relapsing tinea unguium with topical anti-fungal cream: a case report. ( 19154619 )
2009
22
Prevalence of tinea pedis, tinea unguium of toenails and tinea capitis in school children from Barcelona. ( 19766517 )
2009
23
Itraconazole concentrations of fingernails and toenails of patients with tinea unguium. ( 18477237 )
2008
24
In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. ( 17714532 )
2007
25
Tinea pedis and tinea unguium in a 7-year-old child. ( 17644724 )
2007
26
Tinea unguium in the north-west of Iran (1996-2004). ( 17604428 )
2007
27
Twelve cases of tinea unguium in a pediatric clinic in 9 years. ( 17123110 )
2007
28
Epidemiology of tinea pedis and toenail tinea unguium in worshippers in the mosques in Adana, Turkey. ( 16361711 )
2005
29
Clinical and mycological study of occult tinea pedis and tinea unguium in dermatological patients from Tokyo. ( 12870199 )
2003
30
Experimental tinea unguium model to assess topical antifungal agents using the infected human nail with dermatophyte in vitro. ( 12525893 )
2002
31
Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. ( 12435679 )
2002
32
Smear positive leprosy with HIV infection, silent neuritis and extensive tinea corporis and tinea unguium in an Indian male. ( 11898467 )
2001
33
Tinea unguium in Lahore, Pakistan. ( 11346265 )
2001
34
Interferon-gamma production in peripheral lymphocytes of patients with tinea pedis: comparison of patients with and without tinea unguium. ( 11270412 )
2001
35
Prevalence and risk factors of tinea unguium and tinea pedis in the general population in Spain. ( 10970362 )
2000
36
Current topics in diagnosis and treatment of tinea unguium in Japan. ( 10091478 )
1999
37
A review of the epidemiology of tinea unguium in the community. ( 10098282 )
1999
38
Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. ( 9205509 )
1997
39
Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. German Collaborative Dermatophyte Drug Susceptibility Study Group. ( 7625820 )
1995
40
The proteolytic activity of strains of T. mentagrophytes and T. rubrum isolated from tinea pedis and tinea unguium infections. ( 7666296 )
1995
41
Short therapy for tinea unguium with terbinafine: four different courses of treatment. ( 8531933 )
1995
42
Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. ( 7477090 )
1995
43
Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. ( 8257124 )
1993
44
KONCPA: a new method for diagnosing tinea unguium. ( 8219416 )
1993
45
Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. ( 1531407 )
1992
46
Aetiology of onychomycosis and tinea unguium. ( 2530843 )
1989
47
A modified method to detect dermatophytes in the diagnosis of tinea unguium. ( 2961845 )
1987
48
A modified method for rapid mycological diagnosis of Tinea unguium in Taiwan, Republic of China. ( 2954779 )
1987
49
Tinea unguium. ( 2960495 )
1987
50
Urea plaster for softening diseased nails in the treatment of tinea unguium. ( 2962190 )
1986
Sources

Variations for Tinea Unguium

About this section

ClinVar genetic disease variations for Tinea Unguium:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh37 Chromosome 2, 191859910: 191859910
2 STAT1 NM_007315.3(STAT1): c.821G> A (p.Arg274Gln) single nucleotide variant Pathogenic rs387906760 GRCh38 Chromosome 2, 190995184: 190995184
Sources

Expression for Tinea Unguium

About this section
Search GEO for disease gene expression data for Tinea Unguium.
Sources

Pathways for Tinea Unguium

About this section

Pathways related to Tinea Unguium according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Type II interferon signaling (IFNG) 1
10.19 HLA-B STAT1
Sources

GO Terms for Tinea Unguium

About this section

Biological processes related to Tinea Unguium according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular amino acid biosynthetic process GO:0008652 8.96 CBSL GPT
2 cholesterol biosynthetic process GO:0006695 8.62 CNBP SQLE

Molecular functions related to Tinea Unguium according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 8.62 CBSL GPT
Sources

Sources for Tinea Unguium

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....